New targets, new hope: Novel drug targets for Curbing Malaria

Mini-Reviews in Medicinal Chemistry

Volumn 12, Issue 3, 2012, Pages 210-226

  Arora, N ^a   Banerjee, A K ^b  

^a CENTRE FOR CELLULAR AND MOLECULAR BIOLOGY   (India)

^b INDIAN INSTITUTE OF CHEMICAL TECHNOLOGY   (India)

Author keywords

Apicoplast; Drug targets; Membrane biosynthesis and transport; Mitochondria; Plasmodium; Proteases; Resistance

Indexed keywords

3 OXOACYL ACYL CARRIER PROTEIN SYNTHASE; AZADIRACHTIN; CARBAMOYL PHOSPHATE SYNTHASE; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE 3; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 5; CYCLIN DEPENDENT KINASE 6; DIHYDROFOLATE REDUCTASE; DOCETAXEL; DOLASTATIN; FOSMIDOMYCIN; GLUTATHIONE REDUCTASE; GUANINE NUCLEOTIDE BINDING PROTEIN; HEAT SHOCK PROTEIN 40; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; ISOPRENOID; LACTATE DEHYDROGENASE; METHIONYL AMINOPEPTIDASE; NAPHTHAZARIN; PROPRANOLOL; PURINE; PYRIMIDINE; REACTIVE OXYGEN METABOLITE; THIOLACTOMYCIN; THIOREDOXIN REDUCTASE; THYMIDYLATE SYNTHASE; UNINDEXED DRUG;

APICOPLAST; APOPTOSIS; CHROMATIN; CITRIC ACID CYCLE; CYTOTOXICITY; DRUG TARGETING; ERYTHROCYTE; FATTY ACID SYNTHESIS; FOLATE METABOLISM; GLYCOLYSIS; HEME SYNTHESIS; HISTONE ACETYLATION; HYDROLYSIS; HYDROPHOBICITY; IC 50; LIPOGENESIS; MALARIA; MEIOSIS; MICROTUBULE; MITOCHONDRION; NONHUMAN; NUCLEIC ACID METABOLISM; PHOSPHOLIPID SYNTHESIS; PHOTOSYNTHESIS; PLASMODIUM BERGHEI; PLASMODIUM FALCIPARUM; PROTEIN DEGRADATION; PROTEIN PROCESSING; REVIEW; RNA INTERFERENCE; SIGNAL TRANSDUCTION;

EID: 84857852709     PISSN: 13895575     EISSN: 18755607     Source Type: Journal    
DOI: 10.2174/1389557511209030210     Document Type: Review

References (272)

1. Murray, C. J. L.; Lopez, A. D. The Global Burden of Disease: A Comprehensive Assessment of Mortality and Disability from Diseases, Injuries, and Risk Factors in 1990 and Projected to 2020, GBD Series Vol. I. Harvard School of Public Health on behalf of the World Health Organization and the World Bank, Cambridge, Massachusetts, 1996.
2. Murray, C.J.; Lopez, A.D. Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet, 1997, 349(9061), 1269-76.
3. Breman, J. G. The Ears of the Hippopotamus: Manifestations, Determinants, and Estimates of the Malaria Burden. American Journal of Tropical Medicine and Hygiene, 2001, 64, Suppl., 1-2, 1-11.
4. Gallup, J. L.; Sachs, J. D. The Economic Burden of Malaria. American Journal of Tropical Medicine and Hygiene, 2001, 64, Suppl., 1, 85-96.
5. Bowman, S.; Lawson, D.; Basham, D.; Brown, D.; Chillingworth, T.; Churcher, C.M. et al. The complete nucleotide sequence of chromosome 3 of Plasmodium falciparum. Nature, 1999, 400, 532-539.
6. Ivens, A. Hurrah for genomic projects! Parasitol Today, 2000, 16, 317-320.
7. Gardner, J.M. The genome of the malaria parasite. Curr. Opin. in Genetics Devel., 1999, 9, 704-708.
8. Gardner, M.J.; Hall, N.; Fung, E.; White, O.; Berriman, M., Hyman, R.W. et al. Genome sequence of human malaria parasite P. falciparum. Nature, 2002, 419, 498-511.
9. Hall, N.; Fung, E.; White, O.; Berriman, M. Sequence of Plasmodium falciparum chromosomes 1, 3-9 and 13. Nature, 2002, 419, 531-534.
10. Hyman, R.W.; Fung, E.; Conway, D.J.; Kurdi, O., Mao, J.; Miranda, M. et al. Sequence of Plasmodium falciparum chromosome 12. Nature, 2002, 419, 534-537.
11. Carlton, J.M.; Adams, J.H.; Silva, J.C.; Bidwell, S.L.; Lorenzi, H.; Caler, E. et al. Comparative genomics of the neglected human malaria parasite Plasmodium vivax. Nature, 2008, 455, 757-763.
12. Rosenthal, P.; Miller, L. The need for new approaches to antimalarial chemotherapy. In: Antimalarial Chemotherapy, Georgiev V., Ed.; Totowa, NJ: Humana Press, 2001; pp. 3-13.
13. Van Dooren, G. G.; Stimmler, L. M.; McFadden, G. I. Metabolic maps and functions of the Plasmodium mitochondrion. FEMS Microbiol. Rev., 2006, 30, 596-630.
14. McFadden, G.I.; Reith, M.; Munholland, J.; Lang-Unnasch, N. Plastid in human parasites. Nature, 1996, 381(6582),482.
15. McFadden, G.I.; Roos, D.S. Apicomplexan plastids as drug targets. Trends Microbiol., 1999, 6, 328-333.
16. Fichera, M.E.; Roos, D.S. A plastid organelle as a drug target in apicomplexan parasites. Nature, 1997, 390, 407-409.
17. Alam, A.; Goyal, M.; Iqbal, M.S.; Pal, C.; Dev, S.; Bindu, S.; Maity, P.; Bandyopadhyay, U. Novel antimalarial drug targets: hope for new antimalarial drugs. Expert Review of Clinical Pharmacology. 2009, 2(5), 469-489.
18. Waller, R.F.; Ralph, S.A.; Reed, M.B.; Su, V.; Douglas, J.D.; Minnikin, D.E. et al. Type II Pathway for Fatty Acid Biosynthesis Presents Drug Targets in Plasmodium falciparum. Antimicrobial Agents and Chemotherapy., 2003, 47, 297-301.
19. Fish, W. R. Lipid and membrane metabolism of the malaria parasite and the African trypanosome, In: Biochemistry and molecular biology of parasites, J. J. Marr and M. Müller Ed.; Academic Press, London, United Kingdom. 1995; pp. 133-145.
20. Holz, G. G. Lipids and the malarial parasite. Bull. W. H. O., 1977, 55,237-248.
21. Vial, G. J.; Ancelin, M. L. Malarial lipids. An overview. Subcell. Biochem. 1992, 18, 259-306.
22. Surolia, N.; Surolia, A. Triclosan offers protection against blood stages of malaria by inhibiting enoyl-ACP reductase of Plasmodium falciparum. Nat. Med., 2001, 7,167-173.
23. Schweizer, E.; Hofmann, J. Microbial type I fatty acid synthases (FAS): major players in a network of cellular FAS systems. Microbiol. Mol. Biol. Rev., 2004, 68,501-517.
24. Smith, S.; Witkowski, A.; Joshi, A. K. Structural and functional organization of the animal fatty acid synthase. Prog. Lipid Res., 2003, 42, 289-317.
25. Campbell, J. W.; Cronan, Jr, J. E. Bacterial fatty acid biosynthesis: targets for antibacterial drug discovery. Annu. Rev. Microbiol., 2001, 55, 305-332.
26. Waller, R. F.; Keeling, P. J.; Donald, R. G. K.; Striepen, B.; Handman, E.; Lang-Unnasch, N. et al. Nuclear-encoded proteins target to the plastid in Toxoplasma gondii and Plasmodium falciparum. Proc. Natl. Acad. Sci. U.S.A., 1998, 95, 12352-12357.
27. Zagnitko, O.; Jelenska, J.; Tevzadze, G.; Haselkorn, R.; Gornicki, P. An isoleucine/leucine residue in the carboxyltransferase domain of acetyl- CoA carboxylase is critical for interaction with aryloxyphenoxypropionate and cyclohexanedione inhibitors. Proc. Natl. Acad. Sci. USA, 2001, 98, 6617-6622.
28. Zuther, E.; Johnson, J.J.; Haselkorn, R.; McLeod, R.; Gornicki, P. Growth of Toxoplasma gondii is inhibited by aryloxyphenoxypropionate herbicides targeting acetyl-CoA carboxylase. Proc. Natl. Acad. Sci. USA. 1999, 96, 13387-13392.
29. Prigge, S.T.; He, X.; Gerena, L.; Waters, N.C.; Reynolds, K.A. The initiating steps of a type II fatty acid synthase in Plasmodium falciparum are catalyzed by pfACP, pfMCAT, and pfKASIII. Biochemistry, 2003, 42, 1160-1169.
30. Serre L.; Swenson, L.; Green, R.; Wei, Y.; Verwoert, I.I.; Verbree, E.C. et al. Crystallization of the malonyl coenzyme A-acyl carrier protein transacylase from Escherichia coli. J. Mol. Biol., 1994, 242, 99-102
31. Keatinge-Clay, A.T.; Shelat, A.A.; Savage, D.F.; Tsai, S.C.; Miercke, L.J.; O'Connell III J.D. et al. Catalysis, specificity, and ACP docking site of Streptomyces coelicolor malonyl-CoA:ACP transacylase. Structure, 2003, 11, 147-154.
32. Zhang, Y. M.; Lu, Y. J.; Rock, C. O. The reductase steps of the type II fatty acid synthase as antimicrobial targets. Lipids, 2004, 39, 1055-1060.
33. Pillai, S.; Rajagopal, C.; Kapoor, M.; Kumar, G.; Gupta, A.; Surolia, N. Functional characterization of β-ketoacyl-ACP reductase (FabG) from Plasmodium falciparum. Biochem. Biophys. Res. Commun., 2003, 303, 387-392.
34. Sharma, S. K.; Kapoor, M.; Ramya, T. N. C.; Kumar, S.; Kumar, G.; Modak, R.; Sharma, S.; Surolia, N.; Surolia, A. Identification, characterization and inhibition of Plasmodium falciparum β-hydroxyacyl-acyl carrier protein dehydratase (FabZ). J. Biol. Chem. 2003, 278, 45661-45671.
35. Kostrewa, D.; Winkler, F.K.; Folkers, G.; Scapozza, L.; Perozzo, R. The crystal structure of PfFabZ, the unique β-hydroxyacyl-ACP dehydratase involved in fatty acid biosynthesis of Plasmodium falciparum. Protein Sci., 2005, 14(6), 1570-1580.
36. Chhibber, M.; Kumar, G.; Parasuraman, P.; Ramya, T. N.; Surolia, N.; Surolia, A. Novel diphenyl ethers: Design, docking studies,synthesis, and inhibition of enoyl ACP reductase of Plasmodium falciparum and Escherichia coli. Bioorg. Med. Chem., 2006, 14 (23), 8086-8098.
37. Freundlich, J. S.; Anderson, J. W.; Sarantakis, D.; Shieh, H. M.; Yu, M.; Valderramos, J. C. et al. Synthesis, biological activity, and X-ray crystal structural analysis of diaryl ether inhibitors of malarial enoyl acyl carrier protein reductase. Part 1: 4¢-Substituted triclosan derivatives. Bioorg. Med. Chem. Lett., 2005, 15, 5247-5252.
38. Freundlich, J. S.; Yu, M.; Lucumi, E.; Kuo, M.; Tsai, H. C.; Valderramos, J. C. et al. Synthesis and biological activity of diaryl ether inhibitors of malarial enoyl acyl carrier protein reductase. Part 2: 2¢-substituted triclosan derivatives. Bioorg. Med. Chem. Lett., 2006, 16, 2163-2169.
39. Kumar, S.; Kumar, G.; Kapoor, M.; Surolia, A.; Surolia, N. Synthesis and evaluation of substituted pyrazoles: Potential antimalarials targeting the enoyl ACP reductase of Plasmodium falciparum. Synth. Commun., 2006, 36 (2), 215-226.
40. Sharma, S. K.; Prasanna, P.; Kumar, G.; Surolia, N.; Surolia, A. Green tea catechins potentiate triclosan binding to enoyl-ACP reductase from Plasmodium falciparum (PfENR). J. Med. Chem., 2007, 50, 765-775.
41. Kumar, G.; Parasuraman, P.; Sharma, S.K.; Banerjee, T.; Karmodiya, K.; Surolia, N. et al. Discovery of a Rhodanine Class of Compounds as Inhibitors of Plasmodium falciparum Enoyl-Acyl Carrier Protein Reductase J Med Chem. 2007, 50(11),2665-2675.
42. Karioti, A.; Skaltsa, H.; Zhang, X.; Tonge, P.J.; Perozzo, R.; Kaiser, M. et al. Inhibiting enoyl-ACP reductase (FabI) across pathogenic microorganisms by linear sesquiterpene lactones from Anthemis auriculata Phytomedicine., 2008, 15(12), 1125-1129.
43. Goodman, C.D.; McFadden, G.I. Fatty Acid Biosynthesis as a Drug Target in Apicomplexan Parasites. Current Drug Targets, 2007, 8, 15-30.
44. Price, A. C.; Choi, K.H.; Heath, R. J.; Li, Z.; White, S. W.; Rock, C. O. Inhibition of β-ketoacyl-acyl carrier protein synthases by thiolactomycin and cerulenin. J. Biol. Chem., 2001,276, 6551-6559.
45. Surolia, A.; Ramya, T.N.; Ramya, V.; Surolia, N. 'FAS't inhibition of malaria. Biochem. J., 2004, 383, 401-412.
46. Jones, S.M.; Urch, J.E.; Brun, R.; Harwood, J.L.; Berry, C.; Gilbert, I.H. Analogues of thiolactomycin as potential antimalarial and anti-trypanosomal agents. Bioorg Med Chem. 2004, 15, 12(4), 683-92.
47. Jones, S.M.; Urch, J.E.; Kaiser, M.; Brun, R.; Harwood, J.L.; Berry, C.; Gilbert, I.H. Analogues of thiolactomycin as potential antimalarial agents. J Med Chem. 2005, 48(19), 5932-41.
48. Kemp, L.E.; Bond, C.S.; Hunter, W.N. Structure of 2C-methyl-Derythritol 2,4 cyclodiphosphate synthase: an essential enzyme for isoprenoid biosynthesis and target for antimicrobial drug development. Proc. Natl Acad. Sci. USA, 2002, 99, 6591-6596.
49. Bloch, K. Sterol molecule: structure, biosynthesis and function. Steroids, 1992, 57(8), 378-383.
50. Rohmer, M.; Knani, M.; Simonin, P.; Sutter, B.; Sahm, H. Isoprenoid biosynthesis in bacteria: a novel pathway for the early steps leading to isopentenyl diphosphate. Biochem. J, 1993, 295, 517-524.
51. Eisenreich, W.; Schwarz, M.; Cartayrade, A.; Arigoni, D.; Zenk, M.H.; Bacher, A. The deoxyxylulose phosphate pathway of terpenoid biosynthesis in plants and microorganisms. Chem. Biol., 1998, 5, R221-R233.
52. Boucher, Y., Doolittle, W.F. The role of lateral gene transfer in the evolution of isoprenoid biosynthesis pathways. Mol. Microbiol., 2000, 37, 703-716.
53. Couto, A.S.; Kimura, E.A.; Peres, V.J.; Uhrig, M.L.; Katzin, A.M. Active isoprenoid pathway in the intra-erythrocytic stages of Plasmodium falciparum: presence of dolichols of 11 and 12 isoprene units. Biochem. J., 1999, 341, 629-637.
54. Rohdich, F.; Eisenreich, W.; Wungsintaweekul, J.; Hecht, S.; Schuhr, C.A.; Bacher, A. Biosynthesis of terpenoids. 2C-Methyl- D-erythritol 2,4-cyclodiphosphate synthase (IspF) from Plasmodium falciparum. Eur. J. Biochem, 2001, 268, 3190-3197.
55. Kuntz, L.; Tritsch, D.; Grosdemange-Billiard, C.; Hemmerlin, A.; Willem, A.; Bach, T.J. et al. Isoprenoid biosynthesis as a target for antibacterial and antiparasitic drugs: phosphonohydroxamic acids as inhibitors of deoxyxylulose phosphate reductoisomerase. Biochem. J., 2005, 386(Pt 1), 127-135.
56. Surolia, N.; Padmanaban, G. de novo biosynthesis of heme offers a new chemotherapeutic target in the human malarial parasite. Biochem. Biophys. Res. Commun., 1992, 187,744-750.
57. Surolia, N.; Padmanaban, G. Chloroquine inhibits heme-dependent protein synthesis in Plasmodium falciparum. Proc. Natl. Acad. Sci. U. S. A., 1991, 88, 4786-4790.
58. Padmanaban, G.; Nagaraj, V. A.; Rangarajan, P.N. Drugs and drug targets against malaria. Current Science, 2007, 92(11), 1545-1555.
59. Varadharajan, S.; Dhanasekaran, S.; Bonday, Z.Q.; Rangarajan, P.N.; Padmanaban, G. Involvement of delta-aminolaevulinate synthase encoded by the parasite gene in de novo haem synthesis by Plasmodium falciparum. Biochem J., 2002, 367, 321-327.
60. Bonday, Z.Q.; Taketani, S.; Gupta, P.D.; Padmanaban, G. Heme biosynthesis by the malarial parasite. Import of deltaaminolevulinate dehydrase from the host red cell. J. Biol. Chem., 1997, 272, 21839-21846.
61. Bonday, Z.Q.; Dhanasekaran, S.; Rangarajan, P.N.; Padmanaban, G. Import of host deltaaminolevulinate dehydratase into the malarial parasite: identification of a new drug target. Nat. Med., 2000, 6, 898-903.
62. Padmanaban, G.; Rangarajan, P.N. Heme metabolism of Plasmodium is a major antimalarial target. Biochem. Biophys. Res. Commun., 2000, 268, 665-668.
63. Sato, S., Tews, I. and Wilson, R.J.M. Impact of a plastid-bearing endocytobiont on apicomplexan genomes. Int. J. Parasitol,. 2000, 30, 427-439.
64. van Dooren, G.G.; Su, V.; D'Ombrain, M.C.; McFadden, G.I. Processing of an apicoplast leader sequence in Plasmodium falciparum and the identification of a putative leader cleavage enzyme. J. Biol. Chem., 2002, 277, 23612-23619.
65. Sato, S.; Clough, B.; Coates, L.; Wilson, R. J. M. Enzymes for heme biosynthesis are found in both the mitochondrion and plastid of the malaria parasite Plasmodium falciparum. Protist, 2004, 155, 117-125.
66. Nagaraj, V.A.; Arumugam, R.; Chandra, N.R.; Prasad, D.; Rangarajan, P.N.; Padmanaban, G. Localisation of Plasmodium falciparum uroporphyrinogen III decarboxylase of the hemebiosynthetic pathway in the apicoplast and characterisation of its catalytic properties. Int. J. Parasitol., 2009, 39, 559-568.
67. Robert, A.; Coppel, Y.; Meunier, B. Alkylation of heme by the antimalarial. drug artemisinin. Chem Commun (Camb.), 2002, 5, 414-415.
68. Egan, T.J. Haemozoin (malaria pigment): a unique crystalline drug target. Targets, 2003, 2,115-124.
69. Clough, B.; Wilson, R. J. M. Antibiotics and the plasmodial plastid organelle. In: Antimalarial Chemotherapy: Mechanisms of Action, Resistance and New Directions in Drug Discovery, P. J. Rosenthal Ed.; Humana Press, Totawa, 2001, pp. 265-286.
70. Ordóñez, C.; Alfonso, J.; Balaña-Fouce, R.; Ordóñez, D. Functional expression of a DNA-topoisomerase IB from Cryptosporidium parvum. J. Biomed. Biotechnol., 2009, 837608. http://www.hindawi.com/journals/jbb/2009/837608/
71. Viard, T.; de la Tour, C.B. Type IA topoisomerases: a simple puzzle? Biochimie., 2007, 89(4),456-67.
72. Wang, J. C. DNA topoisomerases. Annual Review of Biochemistry, 1996, 65, 635-692.
73. Champoux, J. J. DNA topoisomerases: structure, function, and mechanism, Annual Review of Biochemistry, 2001, 70, 369-413.
74. Corbett, K.D.; Berger, J.M. Structure, molecular mechanisms, and evolutionary relationships in DNA topoisomerases. Annual Review of Biophysics and Biomolecular Structure, 2004, 33, 95-118.
75. Reguera, R.M.; Redondo, C.M.; Gutierrez de Prado, R.; Pérez-Pertejo, Y.; Balaña-Fouce, R. DNA topoisomerase I from parasitic protozoa: A potential target for chemotherapy. Biochim. Biophys. Acta., 2006, 1759(3-4),117-31.
76. Bakshi, R.P.; Shapiro, T.A. DNA topoisomerases as targets for antiprotozoal chemotherapy, Mini Rev. Med. Chem., 2003, 3, 597-608.
77. Wang, J.C. DNA topoisomerases as targets of therapeutics: an overview. Adv. Pharmacol., 1994, 29, 1-19.
78. Das, A.; Dasgupta, A.; Sengupta, T.; Majumder, H.K. Topoisomerases of kinetoplastid parasites as potential chemotherapeutic targets. Trends Parasitol., 2004, 20, 381-387.
79. Capranico, G.; Zagotto, G.; Palumbo, M. Development of DNA topoisomerase-related therapeutics: a short perspective of new challenges. Curr. Med. Chem. Anticancer Agents, 2004, 4, 335-345.
80. Bodley, A.L.; Cumming, J.N.; Shapiro, T.A. Effect of camptothecin, a topoisomerase I inhibitor on Plasmodium falciparum. Biochem. Pharmacol., 1998, 55,709-71.
81. Walker, R.A.; Saunders, N.; Lawson, A.J. et al. Use of a LightCycler gyrA mutation assay for rapid identification of mutations conferring decreased susceptibility to ciprofloxacin in multiresistant Salmonella enterica serotype typhimurium DT104 isolates. J of Clin Microbiol., 2001, 39, 1443-1448.
82. Onodera, Y.; Tanaka, M.; Sato, K. Inhibitory activity of quinolones against DNA gyrase of Mycobacterium tuberculosis. J Antimicrob Chemother., 2001, 47, 447-450.
83. Gray, M.W.; Lang, B.F. Transcription in chloroplasts and mitochondria: a tale of two polymerases. Trends Microbiol., 1998, 6,1-3.
84. Wilson, R.J.M.; Denny, P.W.; Preiser, P.R. et al. Complete gene map of the plastid-like DNA of the malaria parasite Plasmodium falciparum. J Mol Biol., 1996, 261, 155-172.
85. Besier, S.; Ludwig, A.; Brade, V.; Wichelhaus, T.A. Molecular analysis of fusidic acid resistance in Staphylococcus aureus. Mol Microbiol., 2003, 47, 463-469.
86. Johnson, R.A.; McFadden, G.I.; Goodman, C.D. Characterization of two malaria parasite organelle translation elongation factor g proteins: the likely targets of the anti-malarial fusidic acid. PLoS One. 2011, 6(6), e20633.
87. Black, F.T.; Wildfang, I.L.; Borgbjerg, K. Activity of fusidic acid against Plasmodium falciparum in vitro. Lancet, 1985, 1, 578-579.
88. Steigbigel, N.; Erythromycin, lincomycin and clindamycin. In: Principles and practice of infectious diseases. New York: Churchill Livinsgtone, G. Mandel, R. Douglas, and J. Bennett Eds.; 1990; 308-317.
89. Clough, B.; Strath, M.; Preiser, P.; Denny, P.; Wilson, R. Thiostrepton binds to malarial plastid rRNA. FEBS Lett., 1997, 406, 123-125.
90. McConkey, G.A.; Rogers, M.J.; McCutchan, T.F. Inhibition of Plasmodium falciparum protein synthesis: targeting the plastid-like organelle with thiosrepton. J Biol Chem, 1997, 272, 2046-2049.
91. Rogers, M.J.; Burkham, Y.V.; McCutchan, T.F.; Draper, D.E. Interaction of thiostrepton with an RNA fragment derived from the plastid-encoded ribosomal RNA of the malaria parasite. RNA, 1997, 3, 815-820.
92. Aminake, M.N.; Schoof, S.; Sologub, L.; Leubner, M.; Kirschner, M.; Arndt, H.D. et al. Thiostrepton and Derivatives Exhibit Antimalarial and Gametocytocidal Activity by Dually Targeting Parasite Proteasome and Apicoplast. Antimicrob Agents Chemother., 2011, 55(4),1338-48.
93. Lell, B.; Kremsner, P. G., Clindamycin as an antimalarial drug; review of clinical trials. Antimicrob. Agents Chemother., 2002, 46, 2315-2320.
94. Ohrt, C.; Willingmyre, G. D.; Lee, P. J.; Knirsch, C.; Milhous, W. K., Assessment of drugs against Plasmodium falciparum in vitro. Antimicrob. Agents Chemother., 2002, 46, 2518-2524.
95. Kumar, A.; Nguyen, K.T.; Srivathsan, S.; Ornstein, B.; Turley, S.; Hirsh, I. et al. Crystals of peptide deformylase from Plasmodium falciparum reveal critical characteristics of the active site for drug design. Structure, 2002, 10(3), 357-67.
96. Bracchi-Ricard, V.; Nguyen, K.T.; Zhou, Y.; Rajagopalan, P.T.; Chakrabarti, D.; Pei, D. Characterization of an eukaryotic peptide deformylase from Plasmodium falciparum. Arch. Biochem. Biophys., 2001, 396, 162-170.
97. Wiesner, J.; Sanderbrand, S.; Altincicek, B.; Beck, E.; Jomaa, H. Seeking new targets for antiparasitic agents. Trends Parasitol., 2001, 17, 7-8.
98. Aldritt, S. M.; Joseph, J. T.; Wirth, D. F. Sequence identification of cytochrome b in Plasmodium gallinaceum. Mol. Cell Biol., 1989, 9, 3614-3620.
99. Feagin, J. E.; Mericle, B. L.; Werner, E.; Morris, M. Identification of additional rRNA fragments encoded by the Plasmodium falciparum 6 kb element. Nucleic Acids Res., 1997, 25, 438-446.
100. Vaidya, A. B. Atavaquone-proguanil combination. In: Antimalarial Chemotherapy: Mechanisms of Action, Resistance and New Directions in Drug Discovery, P. J. Rosenthal Ed.; Totawa, Humana Press, 2001, pp. 203-218.
101. Kouzarides, T. Chromatin modifications and their function. Cell, 2007, 128,693-705.
102. Cui, L.; Miao, J. Chromatin-Mediated Epigenetic Regulation in the Malaria Parasite Plasmodium falciparum. Eukaryotic Cell, 2010, 9(8), 1138-1149.
103. Agbor-Enoh, S.; Seudieu, C.; Davidson, E.; Dritschilo, A.; Jung, M. Novel Inhibitor of Plasmodium Histone Deacetylase That Cures P. berghei-Infected Mice. Antimicrob Agents Chemother., 2009, 53(5), 1727-1734.
104. Chaal, B.K.; Gupta, A.P.; Wastuwidyaningtyas, B.D.; Luah, Y.H.; Bozdech, Z. Histone deacetylases play a major role in the transcriptional regulation of the Plasmodium falciparum life cycle. PLoS Pathog., 2010, 6, e1000737.
105. Duraisingh, M.T.; Voss, T.S.; Marty, A.J.; Duffy, M.F.; Good, R.T.; Thompson, J.K. et al. Heterochromatin silencing and locus repositioning linked to regulation of virulence genes in Plasmodium falciparum. Cell, 2005, 121, 13-24.
106. Freitas-Junior, L.H.; Hernandez-Rivas, R.; Ralph, S.A.; Montiel- Condado, D.; Ruvalcaba-Salazar, O.K.; Rojas-Meza, A.P. et al. Telomeric heterochromatin propagation and histone acetylation control mutually exclusive expression of antigenic variation genes in malaria parasites. Cell, 2005, 121, 25-36.
107. Voss, T.S.; Tonkin, C.J.; Marty, A.J.; Thompson, J.K.; Healer, J.; Crabb, B.S. et al. Alterations in local chromatin environment are involved in silencing and activation of subtelomeric var genes in Plasmodium falciparum. Mol. Microbiol., 2007, 66,139-150.
108. Cui, L.; Miao, J.; Cui, L. Cytotoxic effect of curcumin on malaria parasite Plasmodium falciparum: inhibition of histone acetylation and generation of reactive oxygen species. Antimicrob. Agents Chemother., 2007, 51, 488-494.
109. Cui, L.; Miao, J.; Furuya, T.; Fan, Q.; Xinyi, L.; Rathod, P.K. et al. Histone Acetyltransferase Inhbitor Anacardic Acid Causes Changes in Global Gene Expression during In vitro Plasmodium falciparum Development. Eukaryot Cell., 2008, 7(7), 1200-1210.
110. Darkin-Rattray, S.J.; Gurnett, A.M.; Myers, R.W.; Dulski, P.M.; Crumley, T.M.; Allocco, J.J. et al. Apicidin: a novel antiprotozoal agent that inhibits parasite histone deacetylase. Proc. Natl. Acad. Sci. USA, 1996, 93, 13143-13147.
111. Dow, G.S.; Chen, Y.; Andrews, K.T.; Caridha, D.; Gerena, L.; Gettayacamin, M. et al. Antimalarial activity of phenylthiazolylbearing hydroxamate-based histone deacetylase inhibitors. Antimicrob. Agents Chemother., 2008, 52, 3467-3477.
112. Andrews, K.T.; Tran, T.N.; Lucke, A.J.; Kahnberg, P.; Le, G.T.; Boyle, G.M. et al. Potent antimalarial activity of histone deacetylase inhibitor analogues. Antimicrob. Agents Chemother., 2008, 52, 1454-1461.
113. Wheatley, N.C.; Andrews, K.T.; Tran, T.L.; Lucke, A.J.; Reid, R.C., Fairlie, D.P. Antimalarial histone deacetylase inhibitors containing cinnamate or NSAID components. Bioorg Med Chem Lett., 2010, 20(23), 7080-7084.
114. Marfurt, J.; Chalfein, F.; Prayoga, P.; Wabiser, F.; Kenangalem, E.; Piera, K.A. et al. Ex vivo activity of histone deacetylase inhibitors against multidrug-resistant clinical isolates of P. falciparum and P. vivax. Antimicrob. Agents Chemother., 2011, 55, 961-966.
115. Keough, D.T.; Ng, A.L.; Winzor, D.J.; Emmerson, B.T.; De Jersey, J. Purification and characterization of Plasmodium falciparum hypoxanthine-guaninexanthine phosphoribosyl transferase and comparison with the human enzyme. Mol. Biochem. Parasitol. 1998, 98, 29-41.
116. Kicsca, G.A.; Long, L.; Hçrig, H.; Fairchild, G.; Tyler, P.C.; Furneaux, R.H.; et al. Immucillin-H, a powerful transition-state analog inhibitor of purine nucleoside phosphorylase, selectively inhibits human T lymphocytes. Proc. Natl. Acad. Sci. USA. 2001, 98, 4593-4598.
117. Biagini, G.A.; O'Neill, P.M.; Nzila, A.; Ward, S.A.; Bray P.G. Antimalarial chemotherapy: young guns or back to the future. Trends Parasitol., 2003, 19,479-487.
118. Rathod, P.K.; Reyes, P. Orotidylate-metabolizing enzymes of the human malarial parasite, Plasmodium falciparum, differ from host cell enzymes. J. Biol. Chem., 1983, 258(5), 2852-2855.
119. Reyes, P.; Rathod, P.K.; Sanchez, D.J.; Mrema, J.E.; Rieckmann, K.N.; Heidrich, H.G. Enzymes of purine and pyrimidine metabolism from the human malaria parasite, Plasmodium falciparum. Mol. Biochem. Parasitol., 1982, 5(5),275-290.
120. Asai, T.; O'Sullivan, W.J.; Kobayashi, M.; Gero, A.M.; Yokogawa, M.; Tatibana, M. Enzymes of the de novo pyrimidine biosynthetic pathway in Toxoplasma gondii. Mol Biochem Parasitol., 1983, 7(2), 89-100.
121. Flores, M.V.; O'Sullivan, W.J.; Stewart, T.S. Characterisation of the carbamoyl phosphate synthetase gene from Plasmodium falciparum. Mol Biochem Parasitol., 1994, 68(2), 315-318.
122. Flores, M.V.; Atkins, D.; Wade, D.; O'Sullivan, W.J.; Stewart, T.S. Inhibition of Plasmodium falciparum proliferation in vitro by ribozymes. J Biol Chem., 1997, 272(27), 16940-16945.
123. Jones, M.E., Spector, L., and Lipmann, F. Carbamoylphosphate, the carbamyl donor in enzymatic citrulline synthesis. J. Am. Chem. Soc., 1955, 77, 819-820.
124. Banerjee, A.K.; Arora, N.; Murty, U.S.N. Aspartate carbamoyltransferase of Plasmodium falciparum as a potential drug target for designing anti-malarial chemotherapeutic agents. Medicinal Chemistry Research, (2011) http://www.springerlink.com/content/71084867q51353k7/ DOI: 10.1007/s00044-011-9757-3.
125. Krungkrai, J.; Krungkrai, S.R.; Phakanont, K. Antimalarial activity of orotate analogs that inhibit dihdroorotase and dihydroorotate dehydrogenase. Biochem. Pharmacol., 1992, 43(6),1295-1301.
126. Krungkrai, S.R.; Aoki, S.; Palacpac, N.M.; Sato, D.; Mitamura, T.; Krungkrai, J. et al. Human malaria parasite orotate phosphoribosyltransferase: functional expression, characterization of kinetic reaction mechanism and inhibition profile. Mol Biochem Parasitol., 2004, 134(2), 245-255.
127. Rathod, P. K.; Gomez, Z. M. Plasmodium yoelii: oral delivery of 5- fluoroorotate to treat malaria in mice. Exp. Parasitol., 1991, 73,512-514.
128. Ittarat, I.; Asawamahasakda, W.; Meshnick, S.R. The effects of antimalarials on the Plasmodium falciparum dihydroorotate dehydrogenase. Exp. Parasito., 1994, 79(1), 50-56.
129. Vaidya, A.B.; Mather, M.W. Mitochondrial Evolution and Functions in Malaria Parasites. Annu. Rev. Microbiol., 2009, 63,249-267.
130. Phillips, M.A.; Gujjar, R.; Malmquist, N.A.; White, J.; El Mazouni, F.; Baldwin, J. et al. Triazolopyrimidine-based dihydroorotate dehydrogenase inhibitors with potent and selective activity against the malaria parasite, Plasmodium falciparum. J. Med. Chem., 2008, 51(12), 3649-3653.
131. Deng, X.; Gujjar, R.; El Mazouni, F.; Kaminsky, W.; Malmquist, N.A.; Goldsmith, E.J. et al. Structural plasticity of malaria dihydroorotate dehydrogenase allows selective binding of diverse chemical scaffolds. J. Biol. Chem., 2009, 284(39), 26999-27009.
132. Patel, V.; Booker, M.; Kramer, M.; Ross, L.; Celatka, C.A.; Kennedy, L.M. et al. Identification and characterization of small molecule inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase. J. Biol. Chem., 2008, 283(50), 35078-35085.
133. Painter, H.J.; Morrisey, J.M.; Mather, M.W.; Vaidya, A.B. Specific role of mitochondrial electron transport in blood-stage Plasmodium falciparum. Nature, 2007, 446(7131), 88-91.
134. Nduati, E.; Hunt, S.; Kamau, E.M.; Nzila, A. 2,4- Diaminopteridinebased compounds as precursors for de novo synthesis of antifolates: a novel class of antimalarials. Antimicrob Agents Chemother., 2005, 54, 3652-3657
135. Ferone, R. Folate metabolism in malaria. Bull. World Health. Organ. 1977, 55, 291-298.
136. Krungkrai, J.; Webster, H.K; Yuthavong, Y. De novo and salvage biosynthesis of pteroylpentaglutamates in the human malaria parasite, Plasmodium falciparum. Mol. Biochem. Parasitol., 1989, 32, 25-37.
137. Wang, P.; Lee, C.S.; Bayoumi, R.; Djimde, A.; Doumbo, O.; Swedberg, G., et al. Resistance to antifolates in Plasmodium falciparum monitored by sequence analysis of dihydropteroate synthetase and dihydrofolate reductase alleles in a large number of field samples of diverse origins. Mol Biochem Parasitol, 1997, 89,161-177.
138. Bzik, D.J; Li, W.B.; Horii, T.; Inselburg, J. Molecular cloning and sequence analysis of the Plasmodium falciparum dihydrofolate reductase-thymidylate synthase gene. Proc Natl Acad Sci USA., 1987, 84, 8360-8364.
139. Brooks, D.R.; Wang, P.; Read, M.; Watkins, W.M.; Sims, P.F.G.; Hyde, J.E. Sequence variation of the hydroxymethyldihydropterin pyrophosphokinase - dihydropteroate synthase gene in lines of the human malaria parasite, Plasmodium falciparum, with differing resistance to sulfadoxine. Eur. J. Biochem., 1994, 224, 397-405.
140. Triglia, T.; Cowman, A.F. Primary structure and expression of the dihydropteroate synthetase gene of Plasmodium falciparum. Proc. Natl. Acad.Sci. USA, 1994, 91, 7149-7153.
141. Peterson, D.S.; Walliker, D.; Wellems, T.E. Evidence that a point mutation in dihydrofolate reductase-thymidylate synthase confers resistance to pyrimethamine in falciparum malaria. Proc. Natl. Acad. Sci. USA., 1988, 85, 9114-9118.
142. Canfield, C.J.; Milhous, W.K.; Ager, A.L.; Rossan, R.N.; Sweeney, T.R.; Lewis, N.J. et al. PS-15: a potent, orally active antimalarial from a new class of folic acid antagonists. Am. J. Trop Med. Hyg., 1993, 49, 121-126.
143. Yuthavong, Y.; Yuvaniyama J.; Chitnumsub, P.; Vanichtanankul, J.; Chusacultanachai, S.; Tarnchompoo, B. et al. Malarial (Plasmodium falciparum) dihydrofolate reductase-thymidylate synthase: structural basis for antifolate resistance and development of effective inhibitors. Parasitology, 2005, 130, 249-259.
144. Nduati, E.; Diriye, A.; Ommeh, S.; Mwai, L.; Kiara, S.; Masseno, V. et al. Effect of folate derivatives on the activity of antifolate drugs used against malaria and cancer. Parasitol. Res., 2008, 102, 1227-1234.
145. Hsiao, L. L.; Howard, R. J.; Aikawa, M.; Taraschi, T. F. Modification of host cell membrane lipid composition by the intraerythrocytic human malaria parasite Plasmodium falciparum. Biochem. J., 1991, 274, 121-132.
146. Witola, W.H.; Pessi, G., El Bissati, K.; Reynolds, J.M.; Mamoun, C.B. Localization of the Phosphoethanolamine Methyltransferase of the Human Malaria Parasite Plasmodium falciparum to the Golgi Apparatus. The Journal of Biological Chemistry, 2006, 281(30), 21305-21311.
147. Ancelin, M. L.; Vial, H. J. Regulation of phosphatidylcholine biosynthesis in Plasmodium-infected erythrocytes Biochim. Biophys. Acta, 1989, 1001, 82-89.
148. Pessi, G.; Kociubinski, G.; Ben Mamoun, C. A pathway for phosphatidylcholine biosynthesis in Plasmodium falciparum involving phosphoethanolamine methylation. Proc. Natl. Acad.Sci. USA, 2004, 101(16), 6206-6211.
149. Vial, H. J., Ben Mamoun, C. In: Molecular Approaches to Malaria, I. W. Sherman, Ed.; American Society for Microbiology, Washington, D. C. 2005; pp. 327-352.
150. Ancelin, M.L.; Calas, M.; Bompart, J.; Cordina, G.; Martin, D.; Ben Bari, M. et al. Antimalarial activity of 77 phospholipid polar head analogs: close correlation between inhibition of phospholipid metabolism and in vitro Plasmodium falciparum growth. Blood, 1998, 91, 1426-1437.
151. Ancelin, M.L.; Calas, M.; Vidal-Sailhan, V.; Herbuté, S.; Ringwald, P.; Vial, H.J. Potent inhibitors of Plasmodium phospholipid metabolism with a broad spectrum of in vitro antimalarial activities. Antimicrob Agents Chemother., 2003, 47,2590-2597.
152. Roggero, R.; Zufferey, R.; Minca, M.; Richier, E.; Calas, M.; Vial, H. et al. Unraveling the mode of action of the antimalarial choline analog G25 in Plasmodium falciparum and Saccharomyces cerevisiae. Antimicrob Agents Chemother., 2004, 48, 2816-24.
153. Choubey, V.; Maity, P.; Guha, M.; Kumar, S.; Srivastava, K.; Puri, S.K.; Bandyopadhyay, U. Inhibition of Plasmodium falciparum choline kinase by hexadecyltrimethylammonium bromide: a possible antimalarial mechanism. Antimicrob. Agents Chemother., 2007, 51(2), 696-706.
154. Ancelin, M. L., Vial, H. J.; Philippot, J. R. Inhibitors of choline transport into Plasmodium-infected erythrocytes are effective antiplasmodial compounds in vitro. Biochem. Pharmacol., 1985, 34,4068-4071.
155. Calas, M.; Ancelin, M.L.; Cordina, G.; Portefaix, P.; Piquet, G.; Vidal-Sailhan, V.; Vial, H.Antimalarial activity of compounds interfering with Plasmodium falciparum phospholipid metabolism: comparison between mono- and bisquaternary ammonium salts. J. Med. Chem., 2000, 43(3), 505-516.
156. Wengelnik, K.; Vidal, V.; Ancelin, M.L.; Cathiard, A.M.; Morgat, J.L.; Kocken, C.H.; Calas, M.; Herrera, S.; Thomas, A.W.; Vial, H.J. A class of potent antimalarials and their specific accumulation in infected erythrocytes. Science, 2002, 295(5558),1311-1314.
157. Vial, H.J.; Wein, S.; Farenc, C.; Kocken, C.; Nicolas, O.; Ancelin, M.L. et al. Prodrugs of bisthiazolium salts are orally potent antimalarials. Proc Natl Acad Sci U S A., 2004, 101(43), 15458-15463.
158. Yeo, H.J.; Sri Widada, J.; Mercereau-Puijalon, O.; Vial, H.J. Molecular cloning of CTP:phosphocholine cytidylyltransferase from Plasmodium falciparum. Eur. J. Biochem., 1995, 233(1), 62-72.
159. Kirk, K.; Staines, H.M.; Martin, R.E.; Saliba, K.J. () Transport properties of the host cell membrane. In: Transport and trafficking in the malaria-infected erythrocyte. G. R. Bock and G. Cardew Eds.; John Wiley & Sons, Ltd., Chichester, UK. 1999; pages 55-73.
160. Staines, H.M.; Dee, B.C.; Shen, M.R.; Ellory, J.C. The effect of mefloquine and volume-regulated anion channel inhibitors on induced transport in Plasmodium falciparum-infected human red blood cells. Blood Cells Mol Dis., 2004, 32(3), 344-348.
161. Krishna, S.; Woodrow, C.I.; Burchmore, R.J.S.; Saliba, K.J.; Kirk, K. Hexose transport in asexual stages of Plasmodium falciparum and Kinetoplastidae. Parasitol. Today, 2000, 16, 516-521.
162. Joet, T.; Eckstein-Ludwig, U.; Morin, C.; Krishna, S. Validation of the hexose transporter of Plasmodium falciparum as a novel drug target. Proc. Natl. Acad. Sci. USA., 2003, 100, 7476-9.
163. McKerrow, J.H.; Sun, E.; Rosenthal, P.J.; Bouvier, J. The proteases and pathogenicity of parasitic protozoa. Annu. Rev. Microbiol., 1993, 47,821-853.
164. Rosenthal P.J.; Meshnick, S.R. Hemoglobin catabolism and iron utilization by malaria parasites. Mol. Biochem. Parasitol., 1996, 83,131-139.
165. Lee, B.J.; Singh, A.; Chiang, P.; Kemp, S.J.; Goldman, E.A.; Weinhouse, M.I. et al. Antimalarial activities of novel synthetic cysteine protease inhibitors. Antimicrob. Agents Chemother., 2003, 47,3810-3814.
166. Coombs, G.H.; Goldberg, D.E.; Klemba, M.; Berry, C.; Kay, J.; Mottram, J.C. Aspartic proteases from Plasmodium falciparum. Trends Parasitol., 2001,17,532-537.
167. Bradshaw, R.A.; Brickey, W.W.; Walker, K.W. N-terminal processing: the methionine aminopeptidase and N-acetyl transferase families. Trends Biochem. Sci., 1998, 23, 263-267.
168. Chen, X.; Chong, C.R.; Shi, L.; Yoshimoto, T.; Sullivan, D.J.; Liu, J.O. Inhibitors of Plasmodium falciparum methionine aminopeptidase 1b possess antimalarial activity. Proc Natl Acad Sci U S A. 2006, 103, 14548-14553.
169. Banumathy, G.; Singh, V.; Tatu, U. Host chaperones are recruited in membrane-bound complexes by Plasmodium falciparum. J Biol Chem., 2002, 277, 3902-3912.
170. Ellis, J. Proteins as molecular chaperones. Nature, 1987, 328, 378-379.
171. Sõti, C.; Nagy, E.; Giricz, Z.; Vígh, L.; Csermely, P.; Ferdinandy, P. Heat shock proteins as emerging therapeutic targets. British Journal of Pharmacology, 2005, 146, 769-780.
172. Sharma, Y.D. Structure and possible function of heat-shock proteins in Plasmodium falciparum. Comp. Biochem. Physiol.B., 1992, 102, 437-444.
173. Pesce, E.R.; Cockburn, I.L.; Goble, J.L.; Stephens, L.L.; Blatch, G.L. Malaria heat shock proteins: drug targets that chaperone other drug targets. Infect Disord Drug Target, 2010, 10(3), 147-57.
174. Foth, B.J.; Ralph, S.A.; Tonkin, C.J.; Struck, N.S.; Fraunholz, M.; Roos, D.S. et al. Dissecting apicoplast targeting in the malaria parasite Plasmodium falciparum. Science, 2003, 299, 705-708.
175. Ramya, T.N.C.; Karmodiya, K.; Surolia, A.; Surolia, N. 15- Deoxyspergualin primarily targets the trafficking of apicoplast proteins in Plasmodium falciparum. J. Biol. Chem., 2007, 282, 6388-6397.
176. Kumar, N.; Koski, G.; Harada, M.; Aikawa, M.; and Zheng, H. Induction and localization of Plasmodium falciparum stress proteins related to the heat shock protein 70 family. Mol. Biochem. Parasitol., 1991, 48, 47-58.
177. Joshi, B.; Biswas, S.; Sharma, Y.D. Effect of heat-shock on Plasmodium falciparum viability, growth and expression of the heat-shock protein "PFHSP70-1" gene. FEBS Lett, 1992, 312, 91-94.
178. Biswas, S.; Sharma, Y.D. Enhanced expression of Plasmodium falciparum heat shock protein PFHSP70-1 at higher temperatures and parasite survival. FEMS Microbiol. Lett., 1994, 124, 425-430.
179. Pavithra, S.R.; Banumathy, G.; Joy, O.; Singh, V.; Tatu, U. Recurrent fever promotes Plasmodium falciparum development in human erythrocytes; J. Biol. Chem., 2004, 279, 46692-46699.
180. Banumathy, G.; Singh, V.; Pavithra, S.R.; Tatu, U. Heat shock protein 90 function is essential for Plasmodium falciparum growth in human erythrocytes; J. Biol. Chem., 2003, 278, 18336-18345.
181. Kumar, R.; Musiyenko, A.; Barik, S. The heat shock protein 90 of Plasmodium falciparum and antimalarial activity of its inhibitor, geldanamycin. Malar. J., 2003, 2, 30.
182. Kumar, R.; Pavithra, S.R.; Tatu, U. Three-dimensional structure of heat shock protein 90 from Plasmodium falciparum: molecular modeling approach to rational drug design against malaria; J. Biosci., 2007, 32, 531-536.
183. Doerig, C.; Meijer, L. Antimalarial drug discovery: targeting protein kinases. Expert Opin. Ther. Targets, 2007, 11, 279-290.
184. Morgan, D. O. Cyclin-dependent kinases: engines, clocks, and microprocessors. Annu. Rev. Cell Dev. Biol., 1997, 13, 261-291.
185. Knockaert, M.; Greengard, P.; Meijer, L. Pharmacological inhibitors of cyclindependent kinases. Trends Pharmacol. Sci., 2002, 23,417-425.
186. Geyer, J.A.; Keenan, S.M.; Woodard, C.L.; Thompson, P.A.; Gerena, L.; Nichols, D.A. et al. Selective inhibition of Pfmrk, a Plasmodium falciparum CDK, by antimalarial 1,3-diaryl-2- propenones. Bioorganic & Medicinal Chemistry Letters, 2009, 19, 7, 1982-1985.
187. Hardcastle, I.R.; Golding, B.T.; Griffin, R.J. Designing inhibitors of cyclin-dependent kinases. Ann. Rev. Pharmacol. Toxicol., 2002, 42,325-348.
188. Sahu, N.K.; Sahu, S.; Kohli, D.V. Novel Molecular Targets for Antimalarial Drug Development. Chem. Biol. Drug Des., 2008,71,287-297.
189. Waters, N.C.; Geyer, J.A. Cyclin-dependent protein kinases as therapeutic drug targets for antimalarial drug development. Expert Opin Ther Targets, 2003, 7, 7-17.
190. Keenan, S.M.; Geyer, J.A.; Welsh, W.J.; Prigge, S.T.; Waters, N.C. Rational inhibitor design and iterative screening in the identification of selective plasmodial cyclin dependent kinase inhibitors. Comb. Chem. High Throughput Screen, 2005, 8, 27-38.
191. Woodard, C.L.; Li, Z.; Kathcart, A.K.; Terrell, J.; Gerena, L.; Lopez-Sanchez, M. et al. Oxindole-Based Compounds Are Selective Inhibitors of Plasmodium falciparum Cyclin Dependent Protein Kinases. J. Med. Chem., 2003, 46 (18), 3877-3882.
192. Bhattacharjee, A.K.; Hartell, M.G.; Nichols, D.A.; Hicks, R.P.; Stanton, B.; van Hamont, J.E. et al. Structure-activity relationship study of antimalarial indolo [2,1-b]quinazoline-6,12- diones (tryptanthrins). Three dimensional pharmacophore modeling and identification of new antimalarial candidates. Eur. J. Med. Chem., 2004, 39, 59-67.
193. Hunt, N.H.; Stocker, R. Oxidative stress and the redox status of malaria-infected erythrocytes. Blood Cells, 1990, 16, 499-526.
194. Becker, K.; Tilley, L.; Vennerstrom, J.L.; Roberts, D.; Rogerson, S.; Ginsburg, H. Oxidative stress in malaria parasite-infected erythrocytes: host-parasite interactions. Int. J. Parasitol., 2004, 34, 163-189.
195. Krauth-Siegel, R.L.; Bauer, H.; Schirmer, R.H. Dithiol proteins as guardians of the intracellular redox milieu in parasites: old and new drug targets in trypanosomes and malaria-causing plasmodia. Angew Chem Int Ed; (2005), 44, pp. 690-715.
196. Fritz-Wolf, K.; Becker, A.; Rahlfs, S.; Harwaldt, P.; Schirmer, R.H.; Kabsch, W. et al. X-ray structure of glutathione Stransferase from the malarial parasite Plasmodium falciparum. Proc. Natl. Acad. Sci. USA., 2003,100, 13821-13826.
197. Herrmann, K.M.; Weaver, L.M. The shikimate pathway. Annu. Rev. Plant Physiol. Plant Mol Biol., 1999, 50, 473-503.
198. Roberts, F.; Roberts, C.W.; Johnson, J.J.; Kyle, D.E.; Krell, T.; Coggins, J.R. et al. Evidence for the shikimate pathway in apicomplexan parasites. Nature, 1998, 393, 801-805.
199. Roberts, C.W.; Roberts, F.; Lyons, R.E.; Kirisits, M.J.; Mui, E.J.; Finnerty, J.R. et al. The shikimate pathway and its branches in apicomplexan parasites. J. Infect. Dis., 2002, 185, S25-S36.
200. Keeling, P. J.; Palmer, J. D.; Donald, R. G., Roos, D. S.; Waller, R. F.; McFadden, G. I. Shikimate pathway in apicomplexan parasites. Nature, 1999, 397, 219-220.
201. Abell, C. () Enzymology and molecular biology of the shikimate pathway. In: Comprehensive Natural Products Chemistry. U. Sankawa ED.; Oxford: Pergamon, Elsevier Science Ltd; 1998; pp. 573-607.
202. Davies, G.M.; Barrett-Bee, K.J.; Jude, D.A.; Lehan, M.; Nichols, W.W.; Pinder, P.E. et al. (6S)-6-fluoroshikimic acid, an antibacterial agent acting on the aromatic biosynthetic pathway. Antimicrob. Agents Chemother., 1994, 38(2), 403-406.
203. Kishore, G.M.; Shah, D.M. Amino acid biosynthesis inhibitors as herbicides. Annu Rev Biochem., 1988, 57, 627-63.
204. McConkey, G.A.; Ittarat, I.; Meshnick, S.R.; McCutchan, T.F. Auxotrophs of Plasmodium falciparum dependent on paminobenzoic acid for growth. Proc. Natl. Acad. Sci. U.S.A., 1994, 91, 4244-4248.
205. McConkey, G.; Pinney, J.W.; Westhead, D.R.; Plueckhahn, K.; Fitzpatrick, T.B.; Macheroux, P. et al. Annotating the Plasmodium genome and the enigma of the shikimate pathway. Trends Parasitol., 2004, 20, 60-65.
206. McRobert, L.; McConkey, G.A. RNA interference (RNAi) inhibits growth of Plasmodium falciparum. Mol. Biochem. Parasitol., 2002, 119, 273-278.
207. Dieckmann, A.; Jung, A. Mechanisms of sulfadoxine resistance in Plasmodium falciparum. Mol.Biochem. Parasitol., 1986, 19,143-147.
208. Arora, N.; Chari, U. V. N. M.; Banerjee, A. K.; Murty, U. S. N. A computational approach to explore Plasmodium falciparum 3D7 Chorismate Synthase. The Internet Journal of Genomics and Proteomics. 2007, Volume 3 Number 1.
209. Tapas, S.; Kumar, A.; Dhindwal, S.; Preeti; Kumar, P. Structural analysis of chorismate synthase from Plasmodium falciparum: A novel target for antimalaria drug discovery. Int J Biol Macromol. 2011.
210. McConkey, G.A. Targeting the shikimate pathway in the malaria parasite Plasmodium falciparum. Antimicrob. Agents Chemother., 1999, 43,175-177.
211. Fitzpatrick, T.; Ricken, S.; Lanzer, M.; Amrhein, N.; Macheroux, P.; Kappes, B. Subcellular localization and characterization of chorismate synthase in the apicomplexan Plasmodium falciparum. Mol. Biol., 2001, 40(1), 65-75.
212. McRobert, L.; Jiang, S.; Stead, A., McConkey, G.A. Plasmodium falciparum: Interaction of shikimate analogues with antimalarial drugs. Exp. Parasitol., 2005, 111,178-181.
213. Haldar, K.; Murphy, S.C.; Milner, D.A.; Taylor, T.E. Malaria: Mechanisms of Erythrocytic Infection and Pathological Correlates of Severe Disease. Annu. Rev. Pathol., 2007, 2, 217-249.
214. Auburn, S.; Fry, A.E.; Clark, T.G; Campino, S.; Diakite, M.; Green, A. et al. Further Evidence Supporting a Role for Gs Signal Transduction in Severe Malaria Pathogenesis. PLoS One, 2010, 1, 5(4), e10017.
215. Harrison, T.; Samuel, B.U.; Akompong, T.; Hamm, H.; Mohandas, N.; Lomasney, J.W. et al. Erythrocyte G protein-coupled receptor signaling in malarial infection. Science., 2003, 19, 301(5640), 1734-1736.
216. Murphy, S.C.; Harrison, T.; Hamm, H.E.; Lomasney, J.W.; Mohandas, N.; Haldar, K. Erythrocyte G protein as a novel target for malarial chemotherapy. PLoS Med., 2006, 3(12), e528.
217. Lang-Unnasch, N.; Murphy, A.D. Metabolic changes of the malaria parasite during the transition from the human to the mosquito host. Annu Rev Microbiol., 1998, 52,561-590.
218. Cameron, A.; Read, J.; Tranter, R.; Winter, V.; Sessions, R.; Brady, R.L. Identification and activity of a series of azolebased compounds with lactate dehydrogenase directed antimalarial activity. J. Biol. Chem., 2004, 279, 31429-31439.
219. Roth Jr., E.F.; Calvin, M.C.; Max-Audit, I.; Rosa, J.; Rosa, R. The enzymes of the glycolytic pathway in erythrocytes infected with Plasmodium falciparum malaria parasites. Blood, 1988, 72, 1922-1925.
220. Mehta, M.; Sonawat, H.M.; Sharma, S. Malaria parasite-infected erythrocytes inhibit glucose utilization in uninfected red cells. FEBS Lett., 2005, 7, 579(27), 6151-6158.
221. Chan, M.; Doreen, S.H.; Sim, T.S. Plasmodium falciparum pyruvate kinase as a novel target for antimalarial drug-screening. Travel Med. Infect. Dis., 2007, 5, 125-131.
222. Dunn, C. R.; Banfield, M. J.; Barker, J. J.; Higham, C. W.; Moreton, K. M.; Turgut-Balik, D. et al. The structure of lactate dehydrogenase from Plasmodium falciparum reveals a new target for anti-malarial design. Nat. Struct. Biol., 1996, 3, 912-915.
223. Razakantoanina, V.; Nguyen Kim, P. P.; Jaureguiberry, G. Antimalarial activity of new gossypol derivatives. Parasitol. Res., 2000, 86, 665-668.
224. Choi, S.; Beeler, A.B.; Pradhan, A.; Watkins, E.B.; Rimoldi, J.M.; Tekwani, B. et al. Generation of oxamic acid libraries: antimalarials and inhibitors of Plasmodium falciparum lactate dehydrogenase. J. Comb. Chem., 2007, 9, 292-300.
225. van Schalkwyk, D.A.; Priebe, W.; Saliba, K.J. The inhibitory effect of 2-halo derivatives of D-glucose on glycolysis and on the proliferation of the human malaria parasite Plasmodium falciparum. J. Pharmacol. Exp. Ther., 2008,327, 511-517.
226. Luduena, R. L. Biochemistry of tubulin. In: Microtubules. K. Roberts and J. S. Hyams, Eds.; Academic Press, Inc., New York. 1979; pp. 65-116.
227. Singh, P.; Rathinasamy, K.; Mohan, R.; Panda, D. Microtubule Assembly Dynamics: An Attractive Target for Anticancer Drugs. IUBMB Life, 2008, 60(6), 368-375.
228. Avila, J. Microtubule functions. Life Sci., 1992, 50(5), 327-34.
229. Jordan, M.A.; Wilson, L. Microtubules as a target for anticancer drugs. Nat Rev Cancer., 2004, 4(4), 253-65.
230. Fennell, B.J.; Naughton, J.A.; Dempsey, E.; Bell, A. Cellular and molecular actions of dinitroaniline and phosphorothioamidate herbicides on Plasmodium falciparum:tubulin as a specific antimalarial target. Mol. Biochem. Parasitol., 2006, 145, 226-38.
231. Bell, A. Microtubule inhibitors as potential antimalarial agents. Parasitol Today, 1998, 14, 234-240.
232. Kappes, B.; Rohrbach, P. Microtubule inhibitors as a potential treatment for malaria. Future Microbiology, 2007, 2(4), 409-23.
233. Jones, I. W.; Denholm, A. A.; Ley, S. V.; Lovell, H.; Wood, A.; Sinden, R. E. Sexual development of malaria parasites is inhibited in vitro by the neem extract azadirachtin, and its semi-synthetic analogues. FEMS Microbiol. Lett., 1994,120, 267-274.
234. Billker, O.; Shaw, M.K.; Jones, I.W.; Ley, S.V.; Mordue, A.J.; Sinden, R.E. Azadirachtin Disrupts Formation of Organised Microtubule Arrays during Microgametogenesis of Plasmodium berghei. Eukuryur. Micrubiul., 2002, 49(6), 489-497.
235. Kappes, B.; Rohrbach, P. Microtubule inhibitors as a potential treatment for malaria. Future Microbiology, 2007, 2(4), 409-423.
236. Chatterji, B.P.; Jindal, B.; Srivastava, S.; Panda, D. Microtubules as antifungal and antiparasitic drug targets. Expert Opin. Ther. Pat., 2011, 21(2), 167-86.
237. Fennell, B.J.; Carolan, S.; Pettit, G.R.; Bell, A. Effects of the antimitotic natural product dolastatin 10, and related peptides, on the human malarial parasite Plasmodium falciparum. J. Antimicrob. Chemother., 2003, 5, 833-841.
238. Fennell, B.J.; Naughton, J.A.; Barlow, J.; Brennan, G.; Fairweather, I.; Hoey, E. et al. Microtubules as antiparasitic drug targets. Expert Opin. Drug Discov., 2008, 3(5), 501-518.
239. Pouvelle, B.; Farley, P.J.; Long, C.A.; Taraschi, T.F. Taxol arrests the development of blood-stage Plasmodium falciparum in vitro and Plasmodium chabaudi adami in malaria-infected mice. J. Clin. Invest., 1994, 94, 413-417.
240. Mitra, A.; Sept, D. Binding and interaction of dinitroanilines with apicomplexan and kinetoplastid alpha-tubulin. J. Med. Chem., 2006, 49, 5226-5231
241. Dieckmann-Schuppert, A.; Franklin, R.M. Compounds binding to cytoskeletal proteins are active against Plasmodium falciparum in vitro. Cell Biol. Int. Rep., 1989, 13, 411-419.
242. Navarrete-Vázquez, G.; Rojano-Vilchis Mde, M.; Yépez-Mulia, L.; Meléndez, V.; Gerena, L.; Hernández-Campos, A. et al. Synthesis and antiprotozoal activity of some 2-(trifl uoromethyl)-1Hbenzimidazole bioisosteres. Eur. J. Med. Chem., 2006, 41, 135-141.
243. Matson, S.W.; Bean, D.W.; George, J.W. DNA helicases:enzymes with essential roles in all aspects of DNA metabolism. Bioessays, 1994, 16, 13-22.
244. Tuteja, N.; Tuteja, R. DNA helicases: the long unwinding road. Nat. Genet., 1996, 13, 11-12.
245. Luking, A.; Stahl, U.; Schmidt, U. The protein family of RNA helicases. Crit Rev Biochem Mol Biol., 1998, 33, 259-296.
246. Tuteja, R. Helicases - feasible antimalarial drug target for Plasmodium falciparum. FEBS J., 2007, 274, 4699-4704.
247. Pyle, A.M. Translocation and unwinding mechanisms of RNA and DNA helicases. Annu. Rev. Biophys., 2008, 37,317-336.
248. Abdelhaleem, M. Helicases: an overview. Methods Mol Biol., 2010, 587, 1-12.
249. Tuteja, N.; Tuteja, R. Prokaryotic and eukaryotic DNA helicases. Essential molecular motor proteins for cellular machinery. Eur J Biochem., 2004, 271, 1835-1848.
250. Delagoutte, E.; von Hippel, P.H. Helicase mechanisms and the coupling of helicases within macromolecular machines. Part II: Integration of helicases into cellular processes. Q Rev Biophys., 2003, 36(1), 1-69.
251. Vindigni, A. Biochemical, biophysical, and proteomic approaches to study DNA helicases. Mol. Biosyst., 2007, 3(4), 266-74.
252. Du, M.X.; Johnson, R.B.; Sun, X.L.; Staschke, K.A.; Colacino, J.; Wang, Q.M. Comparative characterization of two DEAD-box RNA helicases in superfamily II: human translation-initiation factor 4A and hepatitis C virus non-structural protein 3 (NS3) helicase. Biochem J., 2002, 363(Pt 1),147-155.
253. Vashisht, A.A.; Pradhan, A.; Tuteja, R.; Tuteja, N. Cold- and salinity stress-induced bipolar pea DNA helicase 47 is involved in protein synthesis and stimulated by phosphorylation with protein kinase C. Plant J., 2005,44(1), 76-87.
254. Hodgman, T.C. A new superfamily of replicative proteins. Nature, 1988, 333, 22-23.
255. Gorbalenya, A. E.; Koonin, E.V.; Donchenko, A.P.; Blinov, V.M. A conserved NTP motif in putative helicases. Nature, 1988, 333, 22.
256. Gorbalenya, A.E.; Koonin, E.V. Helicases: amino acid sequence comparisons and structure-function relationship.Curr. Opin. Struc. Biol., 1993, 3, 419-429.
257. Tanner, N.K. The newly identified Q motif of DEAD box helicases is involved in adenine recognition. Cell Cycle, 2003, 2, 18-19.
258. Gorbalenya, A.E.; Koonin, E.V.; Donchenko, A.P., Blinov, V.M. A novel superfamily of nucleoside triphosphate-binding motif containing proteins which are probably involved in duplex unwinding in DNA and RNA replication and recombination. FEBS Lett. 1988, 1, 235(1-2), 16-24.
259. Gorbalenya, A.E.; Koonin, E.V.; Donchenko, A.P.; Blinov, V.M. Two related superfamilies of putative helicases involved in replication, recombination, repair and expression of DNA and RNA genomes. Nucleic Acids Research, 1989, 17, 4713-4730.
260. Linder, P.; Lasko, P.F.; Ashburner, M.; Leroy, P.; Nielsen, P.J.; Nishi, K. et al. Birth of the D-E-A-D box. Nature, 1989, 337, 121-122.
261. Tuteja, R.; Pradhan, A. Unraveling the 'DEADbox' helicases of Plasmodium falciparum. Gene, 2006, 376, 1-12.
262. de la Cruz, J.; Kressler, D.; Linder, P. Unwinding RNA in Saccharomyces cerevisiae: DEAD-box proteins and related families. Trends Biochem Sci., 1999, 24, 192-198.
263. Tsu, C.A.; Kossen, K.; Uhlenbeck, O.C. The Escherichia coliDEAD protein DbpA recognizes a small RNA hairpin in 23S rRNA. RNA, 2001, 7, 702-709.
264. Singleton, M.R.; Wigley, D.B. Modularity and specialization in superfamily 1 and 2 helicases. J. Bacteriol., 2002, 184, 1819-1826.
265. Song, P.; Malhotra, P.; Tuteja, N.; Chauhan, V.S. RNA helicaserelated genes of Plasmodium falciparum and Plasmodium cynomolgi. Biochem. Biophys. Res. Commun., 1999, 255, 312-316.
266. Seow, F.; Sato, S., Janssen, C.S.; Riehle, M.O.; Mukhopadhyay, A.; Phillips, R.S. et al. The plastidic DNA replication enzyme complex of Plasmodium falciparum. Mol Biochem Parasitol., 2005, 141, 145-153.
267. Suntornthiticharoen, P.; Petmitr, S.; Chavalitshewinkoon-Petmitr, P. Purification and characterization of a novel 3¢)5¢ DNA helicase from Plasmodium falciparum and its sensitivity to anthracycline antibiotics. Parasitology, 2006, 133, 389-398.
268. Tuteja, R.; Tuteja, N.; Malhotra, P.; Chauhan, V.S. Replication fork-stimulated eIF-4A from Plasmodium cynomolgi unwinds DNA in the 3¢ to 5¢ direction and is inhibited by DNA-interacting compounds. Arc. Biochem. Biophys., 2003, 414,108-114.
269. Pradhan, A.; Tuteja, R. Plasmodium falciparum DNA helicase 60:ds RNA and antibody-mediated inhibition of malaria parasite growth and downregulation of its enzyme activities by DNAinteracting compounds. FEBS J., 2006, 273, 3545-3556.
270. Perez, E.E.; Wang, J.; Miller, J.C.; Jouvenot, Y.; Kim, K.A.; Liu, O. et al. Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases. Nat Biotechnol., 2008, 26, 808-816.
271. Cradick, TJ, Keck K, Bradshaw S, Jamieson AC, McCaffrey AP: Zinc-finger nucleases as a novel therapeutic strategy for targeting hepatitis b virus DNAs. Mol Ther., 2010, 2010,16.
272. Nain, V.; Sahi S.; Verma, A. CPP-ZFN: A potential DNA-targeting anti-malarial drug. Malaria Journal., 2010, 9,258-263.